UPC Court of Appeal refuses to revive VMR’s European vape patent, upholding lack of inventiveness

Jan.06
UPC Court of Appeal refuses to revive VMR’s European vape patent, upholding lack of inventiveness
The Unified Patent Court’s Court of Appeal declined on Dec. 29 to revive a European patent held by VMR Products LLC, upholding a finding that the patent is not inventive over earlier devices. The decision said adding a window in the vape’s outer shell to reveal the internal cartridge holding vape liquid was an obvious, routine adaptation based on an earlier U.S. patent and general knowledge.

Key Takeaways

 

• Court: Unified Patent Court Court of Appeal

• Decision date: Dec. 29, 2025

• Issue: window in outer shell to view cartridge/cartomizer holding vape liquid

• Outcome: no inventive step; amendment attempts rejected

• Patent: EP3456214; challenger NJOY Netherlands BV

 


 

2Firsts, January 6, 2026  – According to Law360, an appeals panel at the Unified Patent Court declined to revive a European patent belonging to vape company VMR, upholding a ruling that the blueprint is not inventive over earlier devices.

 

The UPC Court of Appeal rejected on Dec. 29 an attempt by VMR Products LLC to restore its protections following a challenge from NJOY Netherlands BV. The newly public decision said it was not inventive to add a window to the vape’s outer shell revealing the internal cartridge that holds vape fluid.

 

The court held that an earlier U.S. patent for an e-cigarette had already laid out a vaping device with all the features of VMR’s patent except for the cartridge window. The decision said a skilled person could develop a vape that allows users to see the cartridge and atomizer mechanism, also known as the cartomizer, based on that earlier patent plus their own general knowledge. The UPC wrote: “The skilled person wishing to provide a vaporizer that facilitates checking the status of the inserted cartomizer, would have considered as a routine adaption the inclusion of a window, a well-known general means for everyday appliances and devices, provided at the obvious place: the cartomizer receiving segment. The result of such a step was readily predictable.”

 

VMR of San Francisco appealed after NJOY persuaded the UPC Court of First Instance in 2024 to squash its patent for a vaping device on the grounds that the design was not inventive. VMR argued the device enabled users to check the status of the internal cartridge and to inspect certain electrical components inside the device.

 

The court said there was nothing in the patent to indicate users would stumble upon such a functional use of the window, and pointed out there was “no synergy” between the positioning of the window in the vape’s outer shell and the position of the battery contact points inside the device. The decision said the device solves the problem of allowing users to check the status of the internal cartridge holding fluid that contains nicotine. The UPC added: “The use of this means in the specific technical context is objectively appropriate and there are no circumstances that would make its application appear impossible, problematic or impracticable,” and noted that another earlier patent “provides an electronic cigarette provided with a cartridge level check window.”

 

The appellate court also rejected VMR’s attempt to rescue its patent with several amendments, ultimately ruling that the blueprint offered no inventive step.

 

A representative for NJOY declined to comment Monday, and representatives for VMR did not immediately respond to a request for comment. The patent-in-suit was EP3456214.

 

2Firsts noted that Altria completed its acquisition of NJOY Holdings, Inc. in 2023 for approximately US$2.75 billion and is now its wholly owned parent company. Juul Labs had acquired VMR Products as early as 2018, making it a subsidiary. That same year, Altria acquired a 35% stake in Juul for US$12.8 billion, but fully exited its equity investment in Juul in 2023. At present, Altria fully owns NJOY, Juul’s primary competitor.

 

Image source: Law360

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
The UK’s Vaping Products Duty and Vaping Duty Stamps Scheme will take effect on October 1, 2026. All vaping liquids manufactured in or imported into the UK will face a flat excise duty of £2.20 per 10ml, whether or not they contain nicotine. Newly manufactured or imported products released onto the UK market from October 1 will require a valid duty stamp, while eligible existing unstamped inventory can continue to be sold through March 31, 2027. From April 1, 2027, all vaping products outside duty suspension must carry a valid stamp.
Sep.03
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australia’s Coalition has unveiled a national illicit-tobacco policy that would cut tobacco excise by 80% and create legal, regulated and taxed adult markets for vaping products and nicotine pouches if it wins government. The plan proposes an excise of A$0.50 per millilitre of e-liquid and A$0.025 per milligram of nicotine in pouches, alongside A$200 million in additional enforcement and a A$60 million three-year public-awareness campaign. The Coalition says the package would narrow the price advantage of illicit products and undermine organised crime, while Labor and public-health groups warn that dramatically cheaper cigarettes could reverse long-term declines in smoking.
Sep.03
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03